Back to search

University of South Florida

Electrogenetherapy of Established B16 Murine Melanoma by Using an Expression Plasmid for HIV-1 Viral Protein R

Abstract

dc:description

Novel therapies and delivery methods directed against malignancies such as melanoma, and particularly metastatic melanoma, are needed. The HIV-1 accessory protein Vpr (viral protein R) has previously been demonstrated to induce G2 cell cycle arrest as well as in vitro growth inhibition/killing of numerous tumor cell lines. In vivo electroporation has been utilized as an effective delivery method for pharmacologic agents as well as DNA plasmids that express "therapeutic" proteins and has been targeted to various tissues including malignant tumors. In this study, we assessed the ability of electroporation-mediated delivery of Vpr plasmid (pVpr) to induce growth attenuation or complete tumor regression in C57BL/6 mice with subcutaneous B16.F10 melanoma lesions. To assess the administration of intratumoral delivery of pVpr with in vivo electroporation, a range of Vpr plasmid dosages, electroporation parameters, and treatment days were evaluated in a subcutaneous B16 murine melanoma model. pVpr was injected directly into the tumors. Immediately following the injection, the subcutaneous tumors were electroporated. Treatment with 25 microgram or 100 microgram of pVpr plus electroporation on days 0 and 4 resulted in complete tumor regressions with long-term survival in 14.3% and 7.1% of the mice, respectively. In order to optimize the treatment regimen, B16 tumors were treated on days 0, 2, and 4 with 100 microgram pVpr plus electroporation which resulted in 50% of the mice with complete tumor regressions and long-term survival. Additional investigations revealed intratumoral Vpr expression and demonstrated that apoptosis was the mechanism by which Vpr caused tumor regression in vivo. This study confirmed that treatment with 100 microgram of pVpr plus electroporation led to durable complete regressions in established murine melanoma lesions. The pVpr plus electroporation treatment regimen has induced complete regressions in mice as well as resistance to tumor challenge in some of the animals. This is the first comprehensive study demonstrating the ability of Vpr, when delivered as a DNA expression plasmid with in vivo electroporation, to induce complete tumor regressions coupled with long- term survival of mice in a highly aggressive and metastatic solid tumor model.

Degree

thesis:*
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Molecular Medicine
Grantor
University of South Florida
Year dc:date
2006

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • McCray, Andrea Nicole
Contributors dc:contributor
  • Richard Heller, Ph.D.
  • Kenneth Ugen, Ph.D.
  • Richard Gilbert, Ph.D.
  • Susan Pross, Ph.D.
  • Burt Anderson, Ph.D.

Subjects

dc:subject × 7

Rights

Language dc:language
EN-US

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.usf.edu/etd/2621

Chain of custody

source
Harvested from
University of South Florida
Base URL
digitalcommons.usf.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

McCray, Andrea Nicole. Electrogenetherapy of Established B16 Murine Melanoma by Using an Expression Plasmid for HIV-1 Viral Protein R. Dissertation thesis, University of South Florida, 2006. https://digitalcommons.usf.edu/etd/2621